REG - ValiRx PLC - NOTIFICATION OF AUSTRALIAN PATENT ALLOWANCE <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

24/05/2017 07:00

RNS Number : 0240G
ValiRx PLC
24 May 2017
ValiRx Plc
("ValiRx" or the "Company")
NOTIFICATION OF AUSTRALIAN PATENT ALLOWANCE FOR THERAPEUTIC COMPOUND, VAL401
London, UK., 24 May 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to report that ValiSeek Limited ("ValiSeek"), the joint venture between ValiRx and Tangent ReprofilingLimited ("Tangent"), has received notification, thatan Australian patent covering VAL401 and its use in the treatment of cancer, has been allowed bythe Australian Patent Office.
ValiSeek was formed to progress VAL401 into Clinical trials for the treatment of lung cancer and other oncology indications.
The allowance of this latestpatent means that ValiSeek now has patent protection for VAL401 in New Zealand, Australia and previously announced patents in the United States. There are also further patents pending for the compound in significantmarkets across the rest of the world, alongside other granted and patentspending for the Group's therapeutic technologies world-wide.
The directors of ValiSeek are pleased to receive this notification of allowance for this patent, further strengthening ValiSeek's portfolio at an important time in VAL401's development pathway.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive
Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.
Tel: +44 (0) 7879 458 364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray/Jo Turner/Richard Nash
Tel: +44 (0) 20 7213 0880
Beaufort Securities Limited (Broker)
Jon Belliss
Tel: +44 (0) 207 382 8300
Notes for Editors 
About ValiSeek
ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company between ValiRx Plc and Tangent Reprofiling Limited, part of the SEEK Group. ValiSeek was formed to progress the drug VAL401 through its remaining preclinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications.
About ValiRx 
ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers.It aims to make a significant contribution in "precision" medicine and science, namely toengineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field. 
ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College. 
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients. 
The Company listed on the AIM Market of the London StockExchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCSEDFMDFWSESI